It is made available under a CC-BY-NC 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.23.23286326;](https://doi.org/10.1101/2023.02.23.23286326) this version posted February 26, 2023. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has grante

# <span id="page-0-17"></span><span id="page-0-15"></span><span id="page-0-12"></span><span id="page-0-10"></span><span id="page-0-9"></span><span id="page-0-7"></span><span id="page-0-6"></span><span id="page-0-5"></span><span id="page-0-4"></span><span id="page-0-2"></span><span id="page-0-1"></span>Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control

<span id="page-0-14"></span><span id="page-0-3"></span>Sophie L. Larsen<sup>1</sup>, Ikgyu Shin<sup>2</sup>, Jefrin Joseph<sup>3</sup>, Haylee West<sup>3</sup>, Rafael Anorga<sup>4</sup>, Gonzalo E. Mena<sup>5</sup>, Ayesha S. Mahmud<sup>6</sup>, and Pamela P. Martinez<sup>2,3\*</sup>

<sup>1</sup>*Program in Ecology, Evolution, and Conservation Biology, University of Illinois Urbana-Champaign, Urbana, IL,*

*USA*

<sup>2</sup>*Department of Statistics, University of Illinois Urbana-Champaign, Urbana, IL, USA*

<span id="page-0-8"></span><sup>3</sup>*Department of Microbiology, School of Molecular and Cellular Biology, University of Illinois Urbana-Champaign, Urbana, IL, USA*

<sup>4</sup>*Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL,*

*USA*

<sup>5</sup>*Department of Statistics, University of Oxford, Oxford, UK* <sup>6</sup>*Department of Demography, University of California, Berkeley, CA, USA*

#### Abstract

<span id="page-0-16"></span><span id="page-0-11"></span>SARS-CoV-2 vaccines were developed and distributed during a global crisis at unprecedented speed. Still, little is known about trends in vaccine uptake over time, their association with socioeconomic inequality, and the impact of these temporal trends on disease control. By analyzing data from dozens of countries, we examined vaccination rates across high and low socioeconomic (SES) groups, showing that socioeconomic disparities in the fraction of the population vaccinated exist at both national and sub-national levels. We also identified two distinct vaccination trends: one characterized by rapid initial roll-out, quickly reaching a plateau; and another trend that is sigmoidal and slow to begin. Informed by these patterns, we implemented an SES-stratified mechanistic model, finding profound differences across the two vaccination types in the burden of infections and deaths. The timing of initial roll-out has a more significant effect on transmission and deaths than the eventual level of coverage or the degree of SES disparity. Surprisingly, the speed of the roll-out is not associated with wealth inequality or GDP per capita of countries. While socioeconomic disparity should be addressed, accelerating the initial rollout for all groups is a broadly accessible intervention and has the potential to minimize the burden of infections and deaths across socioeconomic groups.

<span id="page-0-13"></span><span id="page-0-0"></span>\* To whom correspondence should be addressed: pamelapm@illinois.edu

# Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory virus first detected in China in late 2019 and declared a pandemic in March 2020. Three years later, SARS-CoV-2 is responsible for over 650 million confirmed cases and over 6.6 million deaths worldwide [\[1\]](#page-10-0). Disparities have been found

<sup>5</sup> in coronavirus disease 2019 (COVID-19) outcomes across demographic groups (e.g. [\[2](#page-10-1)[–4\]](#page-10-2)), as well as the consequences of racial and socioeconomic disparities in infection fatality rates and all-cause mortality, [\[2,](#page-10-1) [5,](#page-10-3) [6\]](#page-10-4), COVID-19 testing rates [\[2,](#page-10-1) [7,](#page-11-0) [8\]](#page-11-1), transmission [\[9\]](#page-11-2), and in the ability to social distance and reduce mobility [\[2,](#page-10-1) [9,](#page-11-2) [10\]](#page-11-3).

This pandemic also prompted an unprecedented global development of hundreds of vaccine candidates, with <sup>10</sup> around two dozen authorized for use [\[11\]](#page-11-4). Vaccination began in late 2020 and the number of administered vaccine doses totals over 13 billion worldwide as of February 2023, exceeding the global population [\[1\]](#page-10-0). Global vaccination has been estimated to have averted at least 14 million deaths [\[12\]](#page-11-5), but there has been unequal distribution of the global vaccine supply between high-income countries and low- and middle-income countries [\[13,](#page-11-6) [14\]](#page-11-7). Mathematical models have been useful in understanding optimal SARS-CoV-2 vaccine

- <sup>15</sup> prioritization strategies based on age [\[15\]](#page-11-8) and vaccine sharing to places with lower vaccine availability [\[16,](#page-11-9) [17\]](#page-11-10). At the same time, recent studies have highlighted the need to incorporate racial and socioeconomic aspects of host heterogeneity into the study of infectious disease dynamics [\[10,](#page-11-3) [18,](#page-11-11) [19\]](#page-11-12) and into vaccine prioritization [\[20\]](#page-12-0). While local heterogeneity in vaccine coverage has also recently been identified at limited time scales [\[21,](#page-12-1) [22\]](#page-12-2), still little is known about the temporal trends of vaccination at the national and subnational levels, the potential differences across socioeconomic status, and their consequences for incidence
- and deaths due to SARS-CoV-2 infections.

Here, we analyze weekly vaccination data from dozens countries and territories, and more than 8000 subnational locations to examine temporal dynamics of vaccination. Our results show that, at the national level, percentage of the population vaccinated is strongly associated with per capita gross domestic prod-

<sup>25</sup> uct (GDP), and at the sub-national level, there are persistent socioeconomic inequalities in vaccine uptake across continents. Strikingly, we also distinguish substantial variability in the speed of the initial roll-out, independent of GDP or continent. By implementing these different vaccination trends into a mechanistic model, we find that a faster vaccine roll-out has the most significant effect on the incidence and mortality than the proportion of population vaccinated in the long-term. Accelerating the initial roll-out can act as an

<sup>30</sup> alternative and accessible intervention for many countries with limited access to the vaccine.

# Results

### Global vaccine coverage and socioeconomic disparity

We analyzed data on vaccination and gross domestic product per capita for 160 countries and territories [\[23–](#page-12-3) [57\]](#page-14-0), finding a significant positive association between the GDP per capita of a country and the percentage <sup>35</sup> of the population vaccinated against SARS-CoV-2 with at least one dose (fig. [1A](#page-2-0)). We found that as of June 2022, 97 of these countries (60%) have at least 50% of their population vaccinated, a finding that is consistent with known disparities in vaccine distribution across country income levels [\[13,](#page-11-6) [14\]](#page-11-7). We also collected publicly available temporal data for 34 countries and territories with a sub-national resolution, selecting those that have at least 50% population coverage by a first dose to adequately capture the temporal

<sup>40</sup> dynamics and with at least 12 sub-national localities reporting in the data so that individual localities do not dominate the SES-based analysis (fig. [1B](#page-2-0)).

<span id="page-2-0"></span>

Figure 1: SARS-CoV-2 vaccine coverage. (A) Association between population vaccinated with at least one dose and gross domestic product (GDP) per capita for 160 countries and territories. Vaccine and population data come from [\[23](#page-12-3)[–55\]](#page-13-0) and were compiled by the Financial Times as of June 22, 2022. GDP data are sourced from World Bank [\[56\]](#page-13-1) and PCBS [\[57\]](#page-14-0). (B) Sub-national vaccination data resolution. Based on publicly available data for places with 50% or more of their population vaccinated with at least one dose, we identified 7 countries/territories with vaccination rates for 100 or more locations, 17 for 21-99, and 10 for 12-20 locations. In this study, we excluded 78 countries that have greater than 50% vaccination coverage due to a lack of high-resolution sub-national data, which are referenced as 'not included' in the legend. Details of the data sources and dates of data collection are reported in tables [S1](#page-0-0) and [S2,](#page-0-1) respectively.

From the 34 countries and territories with available temporal data, we split the localities at the sub-national level into quantiles based on measures representative of socioeconomic status (SES) such as income or poverty rates (table [S1\)](#page-0-0). We then analyze the vaccination temporal trends of 81 places by SES, spanning 26

- <sup>45</sup> countries from 5 continents, 33 states of the United States and 24 states of Brazil, and a range of national GDP per capita. We find that high SES groups are experiencing higher rates of vaccination than low SES in 83% of the places analyzed (fig. [2](#page-3-0) and fig. [S1\)](#page-0-2), a disparity that persists over time in the majority of cases (fig. [S2](#page-0-3) and fig. [S3\)](#page-0-4). We further analyzed the degree of disparity using two metrics, the ratio and the difference for the average, the maximum, and the percentage of the population vaccinated at the final week
- <sup>50</sup> (fig. [S4-](#page-0-5)[S5,](#page-0-6) table [S3\)](#page-0-7). Across these 6 metrics, we found that California (United States,CA), Florida (United States, FL), Colombia, Malaysia, and Israel are places that have the highest disparity, while Argentina, Amapa (Brazil, AP), Republic of Korea, and Finland have some of the least disparity observed. We also identified places with disparities that favor low over high SES groups, as is the case of Amazonas (Brazil, AM) and Nevada (United States, NV).
- <sup>55</sup> In order to evaluate possible biases of the quantile-based analysis due to the relative inequality within each location, we evaluated the degree of disparity as a function of the spatial resolution of the quantile-based analysis. We found no significant association in most pairwise comparisons across the six disparity metrics evaluated (fig. [S6\)](#page-0-8). We also analyzed the Lorenz curves for 83 places and estimated a corresponding Gini coefficient of vaccine inequality, finding that vaccines are unequally distributed, with a wide range of Gini
- <sup>60</sup> values (fig. [S7\)](#page-0-9). Using publicly reported Gini indices of income inequality for countries/states (sources in table [S6\)](#page-0-7), we found a significant association between the Gini coefficients of vaccine disparity and the Gini index of income inequality (fig. [S8,](#page-0-10) [S9\)](#page-0-11), and with the quantile-based analysis (fig. [S10\)](#page-0-12), suggesting that socioeconomic inequality is a likely driver of vaccine inequity across countries/states.

#### Distinct vaccination temporal trends

 Inspired by a method traditionally used in ecology [\[58\]](#page-14-1), enzyme kinetics [\[59\]](#page-14-2), and life expectancy [\[60\]](#page-14-3), we fit a functional response  $f(t)$  to the percentage of the population vaccinated over time  $t$  (eq. [1\)](#page-4-0), starting at the first week of available data for each country. This allows us to quantify for each country/state the potential maximum percentage of the population vaccinated  $V_m$ , the week at which half of the vaccination potential is reached  $W_h$ , and a standard parameter  $k$  that relates to the shape of the temporal trend.

<span id="page-3-0"></span>

Continent - Africa - Asia - Europe - North America - South America Observed · High SES · Low SES Fit - High SES · Low SES

Figure 2: Observed (points) and predicted (lines) temporal trends of first-dose COVID-19 vaccine coverage at the sub-national level for high (solid) and low (dashed) SES groups, spanning 26 countries. A remaining 9 places are analyzed in figure [S1,](#page-0-2) and full list of excluding factors are described in the supplementary text. Week 0 is the first week available in the data.

<span id="page-4-1"></span>

Figure 3: Parameters from the functional response fitting and the two temporal trends identified using the Gaussian mixture model [\[61\]](#page-14-4). (A) Vaccination trends over time for concave (teal) and sigmoidal (purple) types. The percentage of the cumulative population vaccinated over time for each type and SES (low in dashed line and high in solid line) were calculated using the average parameters for each type based on the classification of the 81 locations shown in figure [2.](#page-3-0) Parameters for each place can be found in table [S4.](#page-0-7) (B) Values for low and high SES of the shape parameter *k*, the week at which half of the vaccination potential is reached *Wh*, and of the potential maximum percentage of the population vaccinated *Vm*, colored by the two temporal trends. Clustering is still apparent when displaying the United States and Brazil as countries rather than states (fig. [S11\)](#page-0-13).

<span id="page-4-0"></span>
$$
f(t) = \frac{V_m t^k}{W_h^k + t^k} \tag{1}
$$

- <sup>70</sup> Our results not only show that the fitting successfully captures the vaccination trends in most places (lines in fig. [2\)](#page-3-0), but we also identified distinct temporal dynamics that vary in shape from a very fast initial roll-out, as is the case for Cape Verde, to sigmoidal trends, like those observed in Malaysia. To further characterize these temporal trends, we fit a finite Gaussian mixture model [\[61\]](#page-14-4) to the values of *Vm*, *Wh*, and *k*, identifying 2 types of dynamics shown in figure [3A](#page-4-1): a rapid initial roll-out, and then slowing down until reaching a
- <sup>75</sup> steady state (concave type), and a slow beginning translated into several weeks of delay in reaching half of the vaccination potential, but with the potential to reach a higher percentage of the population vaccinated (sigmoidal type).

While the cluster algorithm is informed by the three parameters, the values of *k* are the most segregated into the two types of temporal trends identified (fig. [3B](#page-4-1)). The concave type includes values of *k* with ranges 80 of  $0.8 - 2.7$ , while the range for the sigmoidal type has ranges of  $2.4 - 5.5$ . While the distribution of  $W_h$ 

- has some degree of overlap, the countries/states classified as sigmoidal types tend to have, on average, a halfway-week falling 8 weeks later than for the concave types, with little difference among high and low SES within each type. In contrast, the potential population vaccinated  $V_m$  shows a less clear partitioning, with average values of 75%, 82%, 82%, and 90%, for concave low SES, concave high SES, sigmoidal
- <sup>85</sup> low SES, and sigmoidal high SES, respectively. When looking at the association of these two temporal classifications with GDP per capita and the Gini coefficient, *V<sup>m</sup>* was significantly associated with wealth inequality (fig [S12\)](#page-0-9). Unexpectedly, we found no significant relationship between shape  $k$  and timing  $W_h$ when each variable is compared to GDP per capita and the Gini coefficient (fig. [S12\)](#page-0-9).

#### Impact of SES and vaccination temporal trends on disease transmission

<sup>90</sup> We used the outputs of the functional response fitting to calculate an average daily vaccination rate (time derivative) for the concave and sigmoidal trends over a 14 month period, finding that the concave type peaks

It is made available under a CC-BY-NC 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.23.23286326;](https://doi.org/10.1101/2023.02.23.23286326) this version posted February 26, 2023. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has grante

around 3 months earlier than the sigmoidal one (fig. [4A](#page-6-0) and fig. [S13\)](#page-0-3). We then implemented these average daily rates in an SES-stratified SEIR model, with the vaccine intervention starting immediately or at month 7. If vaccination is started immediately, there is a larger impact, and a concave strategy is optimal for the

- first 12 months, until cases begin to rise (fig. [4B](#page-6-0)), likely due to the waning of immunity. Since the vaccines for SARS-CoV-2 were not available until after several months, we consider the scenario where vaccination starts at  $t = 7$  months to be more realistic, in which a faster initial roll-out (concave type) also reduces the incidence the most (fig. [4C](#page-6-0)). For the remaining analyses, we assume the latter scenario.
- We then examined concave and sigmoidal vaccination strategies under 4 different scenarios of disparities <sup>100</sup> against a no-vaccination scenario considering: (i) the average parameters for each socioeconomic group (Disparity: average), (ii) an extreme case of disparity between high and low SES (Disparity: worst case), (iii) the average parameters disregarding socioeconomic group (Equity: average), and (iv) having the low SES group be vaccinated at the same rate as the high SES group (Equity: best case). These results show that a substantial percentage of cases can be averted by moving from the worst-case disparity to any other <sup>105</sup> scenario, when compared to a no-vaccination case (fig. [4D](#page-6-0)), with a reduction of up to 16% in the 'Equity:
- best case' strategy. Moreover, we find that a faster initial roll-out is always better to avert cases, reflected in an additional 24-25% of cases averted when moving from sigmoidal to concave type. This effect is slightly stronger for the mortality case, with 25-27% of deaths averted (fig. [S14D](#page-0-14)).
- Our findings suggest that both the temporal trend and the disparity can have a substantial impact on the <sup>110</sup> outcomes. However, the effects of changes in individual parameters cannot be isolated. To this end, we independently varied  $W_h$  for high SES from 5 to 30 weeks and the  $V_m$  from 50% to 100%, fixing a constant disparity in the parameters for the 'disparity: worst-case' and 'equity: best case' scenarios (fig. [4E](#page-6-0)). Intuitively, no matter the type of concave or sigmoidal dynamics, having a higher potential of people vaccinated with an earlier halfway week is always better for both cases (fig. [4E](#page-6-0)) and deaths (fig. [S14E](#page-0-14)). We also found
- 115 the halfway week has a stronger effect on the outcomes than  $V_m$ . For instance, if we analyze the equity scenario for both  $W_h$  and  $V_m$  (top-left corner in figure [4E](#page-6-0)), the cases averted could be as low as 60% (concave) or 40% (sigmoidal) if the halfway week is 30, even if the maximum vaccinated is 100%. In contrast, if we look at  $V_m = 50\%$  and  $W_h = 5$ , the cases averted are around 80% in both concave and sigmoidal types.

When comparing across types, the sigmoidal dynamics are more sensitive to the values of *Wh*, where the 120 outcomes are worst at higher values of  $W_h$ , compared to the concave, illustrated in the 20% difference in cases averted when  $V_m = 100\%$  and  $W_h = 30$ . The association of a lower halfway week in countries/states classified as concave may contribute to why concave dynamics are optimal in figure [4D](#page-6-0). When we estimated the infections averted for the values of  $W_h$  and  $V_m$  obtained from the data fitting (illustrated by the white dots), we found that the majority of places with concave vaccination temporal trends would lead to 70%-90% <sup>125</sup> of infections averted, compared to a majority ranging from 50% to 70%, in the case of sigmoidal trends.

To further understand the impact of socioeconomic disparity, we compared the outcomes of the best-case equity and worst-case disparity scenarios, at a given set of *V<sup>m</sup>* and *W<sup>h</sup>* values (fig. [4F](#page-6-0)). We find that difference is minimal under a fast initial roll-out ( $W_h = 5$ ) and a max. coverage ( $V_m = 100\%$ ), reflected in only a 5% and 6% difference between best-case equity and worst-case disparity, for concave and sigmoidal, respec-

130 tively. Counter-intuitively, a low coverage  $(V_m = 50\% - 64\%)$  together with a fast roll-out  $(W_h = 5 - 14)$ could generate the biggest gap between equity and disparity scenarios. However, this scenario seems to be unlikely as it isn't represented in the parameter combinations estimated from the data (white dots). These analyses also show that while the values obtained from fitting the data fall in areas of the parameter space with low differences between both scenarios, socioeconomic disparity could lead to higher differences in

<sup>135</sup> the cases averted under the sigmoidal type, reflected in more areas with a difference greater than 15%.

Finally, when comparing across the two types, the results show that the concave dynamics are optimal for most of the parameter space, independent of the socioeconomic disparity (fig. [4G](#page-6-0)), and with the biggest difference observed at  $W_h = 30$  and  $V_m = 100\%$ . However, if the initial roll-out is unusually fast (e.g.  $W_h = 5$  weeks), sigmoidal becomes optimal. Under these extreme conditions, sigmoidal and concave <sup>140</sup> trends are very similar up to the halfway week, when sigmoidal rapidly overtakes concave and reaches the potential maximum vaccinated relatively fast (fig. [S15\)](#page-0-15). This further supports that a fast roll-out in the early weeks of vaccination drives a higher percentage of cases averted. Still, the area of the parameter space where sigmoidal is optimal results in only a 5-10% difference in the cases averted, indicating that the effect is weak (Fig. [4G](#page-6-0)). Similar results are shown for deaths averted (Fig. [S14\)](#page-0-14).

<span id="page-6-0"></span>

Figure 4: (A) Average daily vaccination rates for each type and SES group (per-country rates shown in fig. [S13\)](#page-0-3). In the sigmoidal type, the parameters for high SES are  $Vm = 89\%$  and  $Wh = 23$  weeks, while for low SES are  $Vm = 82.5\%$  and  $Wh = 24$  weeks. For both SES groups,  $k = 3.23$ , the average across SES. In the concave type, the parameters for high SES are  $Vm = 82.2\%$  and  $Wh = 14$  weeks while for low SES they are  $Vm = 75.5\%$ and  $Wh = 15$  weeks. For both SES groups,  $k = 1.58$ . (B) Cumulative cases per 10,000 with vaccination starting immediately. (C) Cumulative cases per 10,000 with vaccination starting at  $t = 7$  months. (D) Cumulative cases per 10,000 after 14 months under 4 scenarios of sociocioeconomic disparity: disparity: average, disparity: worst case (95th percentile), equity: average (averaging high SES and low SES parameters), and equity: best case (assuming vaccination of the low SES group follow the same parameters as the high SES group. (E) Cases averted by vaccination. Keeping  $k = 1.58$  for concave and  $k = 3.23$  for sigmoidal, we fixed the low SES parameters at a constant disparity from high SES based on the 95th percentiles of the observed data  $(\Delta V m = 21\%, \Delta W h = 6$  weeks), or considered low SES parameters equal to high SES (equity) (fig. [S16\)](#page-0-16). The effect of varying parameter *k* can be found in figure [S17.](#page-0-17) (F) The difference in cases averted under the best-case equity scenario and worst-case disparity, for both concave and sigmoidal types. (G) The difference in cases averted under concave versus sigmoidal types, for both best-case equity and worst-case disparity. Average high SES parameters are illustrated with a cross, while country-specific parameters for high SES are shown with dots. Model parameters are listed in table [S5.](#page-0-7)

## 145 Discussion

By analyzing publicly available data at the national and sub-national level, we examine different aspects of temporal trends in vaccination with a first dose against SARS-CoV-2, the association with socioeconomic disparities, and the impact on overall transmission and mortality. Socioeconomic and racial disparities have been previously identified in SARS-CoV-2 incidence [\[2,](#page-10-1) [18,](#page-11-11) [62\]](#page-14-5) and in vaccination in a few places [\[21,](#page-12-1) [22\]](#page-12-2). <sup>150</sup> We validated these findings at the global level by showing a significant association between the fraction of

the population vaccinated with at least one dose and gross domestic product per capita, in line with prior observation that the global distribution of vaccines has been highly heterogeneous [\[13,](#page-11-6) [17\]](#page-11-10).

While the impact of SARS-CoV-2 vaccination on disease outcomes has been previously studied (e.g. [\[12,](#page-11-5) [15,](#page-11-8) [16\]](#page-11-9)), less understood has been the extent of heterogeneity in vaccination temporal trends and its con-<sup>155</sup> sequences for disease outcomes. To this end, we characterized weekly vaccination uptake of 81 locations, disaggregated by SES, finding that most countries and states experience inequity in vaccine administration in favor of high SES groups, which do not resolve over time. Additionally, the temporal trends vary widely in shape and speed of the vaccination roll-out, which we classified as concave or sigmoidal types. We showed that concave dynamics tend to have a faster initial roll-out, which is reflected in a higher number of cases <sup>160</sup> and deaths averted due to vaccination. Critically, the timing of vaccination is not associated with wealth inequality or GDP per capita, where, for example, Cape Verde has implemented a faster timing compared to

- many high GDP countries such as Belgium, which experienced a very slow initial roll-out. These findings suggest a broadly accessible intervention where the timing rather than allocation of vaccines can be modified early on, providing a broad benefit to the population, even when the entire population cannot be vaccinated
- <sup>165</sup> due to limited stock. We also show that speeding up the timing of vaccine roll-out can be as effective as modifying the socioeconomic disparity, which may be more challenging to address in the short term due to structural inequities in factors such as healthcare or transportation, especially given our finding that wealth inequality is correlated with vaccine disparity.
- Our paper should be considered in light of the following limitations. Previous work has shown that for <sup>170</sup> influenza, association between SES and vaccination is often dependent on the SES measure selected [\[63\]](#page-14-6). This study is limited by the availability of vaccine and socioeconomic data at a high spatial resolution for countries, especially on the African continent. It is therefore not possible to know with certainty what happens at the individual level, leading to the potential for ecological fallacy. We analyzed first dose coverage but trends may differ for second dose or booster. First dose coverage may vary in quality as a long-term <sup>175</sup> vaccination strategy depending on the quality of immune response [\[64\]](#page-14-7). While we did not study the causes of socioeconomic heterogeneity in vaccination, access and intent to vaccinate can vary widely across different countries, and for the case of SARS-CoV-2, it has been linked to demographic factors including income, race, political affiliation, and education [\[21,](#page-12-1) [65–](#page-14-8)[68\]](#page-14-9). This analysis is also agnostic to age structure in the population and this limits the quantification of overall burden. Finally, we used a mechanistic SEIR model <sup>180</sup> that did not consider non-pharmaceutical interventions or pathogen evolution, which could impact intent to vaccinate.

To summarize, we have analyzed the temporal trends of vaccination from thousands of places across 5 continents showing not only that vaccine inequity exists within and between countries, but also that the speed of the roll-out can play a crucial role in the impact on disease incidence, and that surprisingly, this

<sup>185</sup> speed is not associated with socioeconomic metrics. By promoting faster initial vaccine uptake, our work outlines concrete steps that can be taken to reduce the impacts of inequitable vaccination on the burden of disease for everyone.

# Methods

### Data collection and processing

- <sup>190</sup> We collected national statistics on the percentage of the population with at least one dose from [\[23](#page-12-3)[–55\]](#page-13-0), which were compiled by the Financial Times, and GDP per capita for these nations from the World Bank [\[56\]](#page-13-1) and Palestinian Central Bureau of Statistics (PCBS) [\[57\]](#page-14-0). We also collected publicly available on vaccination, SES, and population size at the sub-national level from countries, territories, and states that have at least 12 locations with both vaccination and SES data to avoid single locations having an outsize
- <sup>195</sup> impact on the dynamics. We excluded countries where less than 50% of the total population had received a first dose, to adequately capture the temporal variation across trends. Sources and dates of collection are listed in tables [S1](#page-0-0) and [S2](#page-0-1) respectively. Within each country and state, locations were grouped into quantiles by relative SES. For countries with 12-20 locations, we used 3 groups; for 21-99 we used 5 groups; for 100 or more we used 10 groups. We then computed the average proportion vaccinated at each week, for the <sup>200</sup> highest and lowest SES groups in each country.

Some of the vaccination data have inconsistent reporting and apparent adjustments to the data over time. Issues with data reporting have been flagged by other authors studying vaccination data in the US [\[22\]](#page-12-2). We discarded data points where the cumulative vaccination was not monotonically increasing by applying the despike() function in R to the final aggregated data, which tracks a window of the median in the data and <sup>205</sup> removes any points outside a specified deviation from that median.

The daily vaccination rates, estimated as an approximation to the first derivative of the fit data, is given by the following expression:

$$
\frac{\% \text{ vaccinationated} - \text{lag}(\% \text{vaccinated})}{\text{week} - \text{lag(week)}
$$
 (2)

### Mechanistic model

We implemented a mechanistic SEIR model of transmission, varying the force of infection, proportion with <sup>210</sup> mild or asymptomatic disease, fatality rate, and vaccination rate by socioeconomic status. Parameter values can be found in table [S5.](#page-0-7) We used the functional response to estimate daily vaccination rates  $\nu(t)$  for both high and low SES under two scenarios of parameter *k*, reflecting the average values of the two clusters identified in the results shown in figure [3.](#page-4-1) The following equations were implemented for the low SES group, and an identical set were implemented for high SES, but changing the parameter values:

It is made available under a CC-BY-NC 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.23.23286326;](https://doi.org/10.1101/2023.02.23.23286326) this version posted February 26, 2023. The copyright holder for this preprint<br>(which was not certified by peer review) is the author/funder, who has grante

$$
\frac{dS_{L1}}{dt} = -\lambda_L S_{L1} - \nu_L(t) S_{L1}
$$
\n
$$
\frac{dE_{L1}}{dt} = \lambda_L S_{L1} - \epsilon E_{L1} - \nu_L(t) E_{L1}
$$
\n
$$
\frac{dI_{L1_A}}{dt} = a_{L1} \epsilon E_{L1} - \gamma_A I_{L1_A}
$$
\n
$$
\frac{dI_{L1_S}}{dt} = (1 - a_{L1}) \epsilon E_{L1} - \gamma_S I_{L1_S}
$$
\n
$$
\frac{dR_{L1}}{dt} = \gamma_A I_{L1_A} + (1 - \alpha_{L1}) \gamma_S I_{L1_S} - \omega R_{L1} - \nu(t) R_{L1}
$$
\n
$$
\frac{dS_{L2}}{dt} = \omega R_{L1} + \omega R_{L2} - k \lambda_L S_{L2} - \nu(t) S_{L2}
$$
\n
$$
\frac{dE_{L2}}{dt} = k \lambda_L S_{L2} - \epsilon E_{L2} - \nu(t) E_{L2}
$$
\n
$$
\frac{dI_{L2_A}}{dt} = a_{L2} \epsilon E_{L2} - \gamma_A I_{L2_A}
$$
\n
$$
\frac{dI_{L2_S}}{dt} = (1 - a_{L2}) \epsilon E_{L2} - \gamma_S I_{L2_S}
$$
\n
$$
\frac{dR_{L2}}{dt} = \nu(t) (S_{L1} + S_{L2} + E_{L1} + E_{L2} + R_{L1}) + \gamma_A I_{L2_A} + (1 - \alpha_{L2}) \gamma_S I_{L2_S} - \omega R_{L2}
$$
\n
$$
\frac{dD_L}{dt} = \alpha_{L1} \gamma_S I_{L1_S} + \alpha_{L2} \gamma_S I_{L2_S}
$$

- 215 In this SEIR model, individuals start in the  $S_1$  class, and become exposed  $(E_1)$  through contact with infectious individuals. Once they become infectious, they can either develop a mild  $(I_{14})$  or severe  $(I_{1s})$ disease. The force of infection weights mild and severe infections equally, based on the observation that mild infections are substantial drivers of transmission [\[69\]](#page-14-10). Infectious individuals can move to the recovery class  $R_1$  with rate  $\gamma$ , and only individuals with severe infections can die with probability  $\alpha$ . We estimated
- <sup>220</sup> infection fatality rate (IFR) for low versus high SES as a weighted average, using the age-based estimates from Santiago, Chile [\[2\]](#page-10-1) and United Nations population structure data for Chile [\[70\]](#page-15-0). We further adjusted to account for the proportion of mild/asymptomatic cases in the model, since only severe cases can die. We ran simulations with a population of 10 million low SES and 10 million high SES individuals, and assuming one exposed individual in each SES group at time 0.
- 225 Immunity from the primary infection wanes after 4 months, when individuals move from  $R_1$  to  $S_2$ . Individuals in non-infected categories can also move directly to  $R_2$  through a vaccine intervention. Individuals in *R*<sup>2</sup> wane their immunity after 8 months. We assume that individuals in the second compartments are less susceptible and less infectious, and there is a slightly higher proportion of mild infections, using the CDC upper bound on asymptomatic cases for both SES groups [\[71\]](#page-15-1). We scaled the infection fatality rate for the
- $I_{S_2}$  class using estimates of vaccine efficacy and waned vaccine immunity against severe disease [\[72,](#page-15-2) [73\]](#page-15-3). Literature on contact patterns across socioeconomic groups is limited. However, it is known that workplace and housing environments differ for low and high SES [\[74,](#page-15-4) [75\]](#page-15-5), SES groups tend to have more mobility within-group than outside of their group [\[9,](#page-11-2) [76\]](#page-15-6), and low SES groups have not been as able to reduce their mobility during the pandemic (e.g. [\[2,](#page-10-1) [10\]](#page-11-3)). For these reasons, we assumed contact rates were asymmetric
- <sup>235</sup> across SES groups. All parameter values are listed in table [S5.](#page-0-7)

The force of infection  $\lambda$ , defined as the infection risk per susceptible individual, is given by:

$$
\lambda_L = \mu c_{LH} \left( \frac{I_{H1} + siI_{H2}}{P_H - D_H} \right) + \mu c_{LL} \left( \frac{I_{L1} + siI_{L2}}{P_L - D_L} \right) \lambda_H = \mu c_{HL} \left( \frac{I_{L1} + siI_{L2}}{P_L - D_L} \right) + \mu c_{HH} \left( \frac{I_{H1} + siI_{H2}}{P_H - D_H} \right)
$$

Where  $\mu$  is the probability of infection given contact,  $c_{ij}$  is the contact rate among SES groups, and *si* is a scale parameter that reduces the infectiousness of individuals that are in the second Infected class *I*2.

## <sup>240</sup> Acknowledgements

We thank the many agencies with publicly available vaccine and socioeconomic data for making it possible to conduct this analysis.

### Author Contributions

S.L.L, A.S.M., and P.P.M. conceptualized the study. S.L.L. and H.W. conducted the literature review. S.L.L, <sup>245</sup> I.S., J.J., and R.A. collected and formatted the data. S.L.L. and P.P.M. analyzed the data, designed and coded the model, and wrote the manuscript. A.S.M. assisted with model design. G.E.M. assisted with the analysis. All authors edited the manuscript.

#### Competing Interests

The authors declare no competing interests.

### <sup>250</sup> References

- <span id="page-10-0"></span>[1] Who coronavirus (covid-19) dashboard. <https://covid19.who.int/>. Accessed: 2022-11-06.
- <span id="page-10-1"></span>[2] Gonzalo E Mena, Pamela P Martinez, Ayesha S Mahmud, Pablo A Marquet, Caroline O Buckee, and Mauricio Santillana. Socioeconomic status determines covid-19 incidence and related mortality in santiago, chile. *Science*, 372(6545):eabg5298, 2021.
- <sup>255</sup> [3] Sarah Miller, Laura R Wherry, and Bhashkar Mazumder. Estimated mortality increases during the covid-19 pandemic by socioeconomic status, race, and ethnicity: Study examines covid-19 mortality by socioeconomic status, race, and ethnicity. *Health Affairs*, 40(8):1252–1260, 2021.
- <span id="page-10-2"></span>[4] Katherine Mackey, Chelsea K Ayers, Karli K Kondo, Somnath Saha, Shailesh M Advani, Sarah Young, Hunter Spencer, Max Rusek, Johanna Anderson, Stephanie Veazie, et al. Racial and ethnic disparities <sup>260</sup> in covid-19–related infections, hospitalizations, and deaths: a systematic review. *Annals of internal medicine*, 174(3):362–373, 2021.
	- [5] Jon Zelner, Rob Trangucci, Ramya Naraharisetti, Alex Cao, Ryan Malosh, Kelly Broen, Nina Masters, and Paul Delamater. Racial disparities in coronavirus disease 2019 (covid-19) mortality are driven by unequal infection risks. *Clinical Infectious Diseases*, 72(5):e88–e95, 2021.
- <span id="page-10-4"></span><span id="page-10-3"></span>265 [6] Hélène E Aschmann, Alicia R Riley, Ruijia Chen, Yea-Hung Chen, Kirsten Bibbins-Domingo, Andrew C Stokes, M Maria Glymour, and Mathew V Kiang. Dynamics of racial disparities in allcause mortality during the covid-19 pandemic. *Proceedings of the National Academy of Sciences*, 119(40):e2210941119, 2022.

- <span id="page-11-0"></span>[7] Aaloke Mody, Kristin Pfeifauf, Cory Bradley, Branson Fox, Matifadza G Hlatshwayo, Will Ross, Vetta <sup>270</sup> Sanders-Thompson, Karen Joynt Maddox, Mat Reidhead, Mario Schootman, et al. Understanding drivers of coronavirus disease 2019 (covid-19) racial disparities: a population-level analysis of covid-19 testing among black and white populations. *Clinical Infectious Diseases*, 73(9):e2921–e2931, 2021.
- <span id="page-11-1"></span>[8] Pricila H Mullachery, Ran Li, Steven Melly, Jennifer Kolker, Sharrelle Barber, Ana V Diez Roux, and Usama Bilal. Inequities in spatial accessibility to covid-19 testing in 30 large us cities. *Social Science* <sup>275</sup> *& Medicine*, 310:115307, 2022.
	- [9] Matan Yechezkel, Amit Weiss, Idan Rejwan, Edan Shahmoon, Shachaf Ben-Gal, and Dan Yamin. Human mobility and poverty as key drivers of covid-19 transmission and control. *BMC public health*, 21(1):1–13, 2021.
- <span id="page-11-4"></span><span id="page-11-3"></span>[10] Michele Tizzoni, Elaine O Nsoesie, Laetitia Gauvin, Marton Karsai, Nicola Perra, and Shweta Bansal. ´ <sup>280</sup> Addressing the socioeconomic divide in computational modeling for infectious diseases. *Nature Communications*, 13(1):1–7, 2022.
	- [11] Daniel M Altmann and Rosemary J Boyton. Covid-19 vaccination: The road ahead. *Science*, 375(6585):1127–1132, 2022.
	- [12] Oliver J Watson, Gregory Barnsley, Jaspreet Toor, Alexandra B Hogan, Peter Winskill, and Azra C
- <span id="page-11-6"></span><span id="page-11-5"></span><sup>285</sup> Ghani. Global impact of the first year of covid-19 vaccination: a mathematical modelling study. *The Lancet Infectious Diseases*, 22(9):1293–1302, 2022.
	- [13] Matthew M Kavanagh, Lawrence O Gostin, and Madhavi Sunder. Sharing technology and vaccine doses to address global vaccine inequity and end the covid-19 pandemic. *Jama*, 326(3):219–220, 2021.
- <span id="page-11-7"></span><sup>290</sup> [14] Moosa Tatar, Jalal Montazeri Shoorekchali, Mohammad Reza Faraji, and Fernando A Wilson. International covid-19 vaccine inequality amid the pandemic: Perpetuating a global crisis? *Journal of global health*, 11, 2021.
- <span id="page-11-9"></span><span id="page-11-8"></span>[15] Kate M Bubar, Kyle Reinholt, Stephen M Kissler, Marc Lipsitch, Sarah Cobey, Yonatan H Grad, and Daniel B Larremore. Model-informed covid-19 vaccine prioritization strategies by age and serostatus. <sup>295</sup> *Science*, 371(6532):916–921, 2021.
	- [16] Caroline E Wagner, Chadi M Saad-Roy, Sinead E Morris, Rachel E Baker, Michael J Mina, Jeremy Farrar, Edward C Holmes, Oliver G Pybus, Andrea L Graham, Ezekiel J Emanuel, et al. Vaccine nationalism and the dynamics and control of sars-cov-2. *Science*, 373(6562):eabj7364, 2021.
- <span id="page-11-10"></span>[17] Sam Moore, Edward M Hill, Louise Dyson, Michael J Tildesley, and Matt J Keeling. Retrospectively <sup>300</sup> modeling the effects of increased global vaccine sharing on the covid-19 pandemic. *Nature Medicine*, pages 1–8, 2022.
	- [18] Kevin C Ma, Tigist F Menkir, Stephen Kissler, Yonatan H Grad, and Marc Lipsitch. Modeling the impact of racial and ethnic disparities on covid-19 epidemic dynamics. *Elife*, 10:e66601, 2021.
- <span id="page-11-12"></span><span id="page-11-11"></span>[19] Jon Zelner, Nina B Masters, Ramya Naraharisetti, Sanyu A Mojola, Merlin Chowkwanyun, and Ryan <sup>305</sup> Malosh. There are no equal opportunity infectors: Epidemiological modelers must rethink our approach to inequality in infection risk. *PLoS computational biology*, 18(2):e1009795, 2022.

12

<span id="page-11-2"></span>

- <span id="page-12-0"></span>[20] Elizabeth Wrigley-Field, Mathew V Kiang, Alicia R Riley, Magali Barbieri, Yea-Hung Chen, Kate A Duchowny, Ellicott C Matthay, David Van Riper, Kirrthana Jegathesan, Kirsten Bibbins-Domingo, et al. Geographically targeted covid-19 vaccination is more equitable and averts more deaths than <sup>310</sup> age-based thresholds alone. *Science advances*, 7(40):eabj2099, 2021.
- 
- <span id="page-12-1"></span>[21] Gil Caspi, Avshalom Dayan, Yael Eshal, Sigal Liverant-Taub, Gilad Twig, Uri Shalit, Yair Lewis, Avi Shina, and Oren Caspi. Socioeconomic disparities and covid-19 vaccination acceptance: a nationwide ecologic study. *Clinical Microbiology and Infection*, 27(10):1502–1506, 2021.
- <span id="page-12-3"></span><span id="page-12-2"></span>[22] Andrew Tiu, Zachary Susswein, Alexes Merritt, and Shweta Bansal. Characterizing the spatiotemporal <sup>315</sup> heterogeneity of the covid-19 vaccination landscape. *MedRxiv*, 2021.
	- [\[](https://www.ascension.gov.ac/covid-19-vaccination-campaign-continues)23] Ascension island government. [https://www.ascension.gov.ac/](https://www.ascension.gov.ac/covid-19-vaccination-campaign-continues) [covid-19-vaccination-campaign-continues](https://www.ascension.gov.ac/covid-19-vaccination-campaign-continues).
	- [24] Ascension. <https://www.sainthelena.gov.sh/ascension-3/>.
- [\[](https://info.gesundheitsministerium.gv.at/opendata.html?lang=en)25] Corona in austria. [https://info.gesundheitsministerium.gv.at/opendata.](https://info.gesundheitsministerium.gv.at/opendata.html?lang=en) <sup>320</sup> [html?lang=en](https://info.gesundheitsministerium.gv.at/opendata.html?lang=en).
	- [\[](https://covid19tracker.ca/vaccinationtracker.html)26] Covid-19 vaccination tracker. [https://covid19tracker.ca/vaccinationtracker.](https://covid19tracker.ca/vaccinationtracker.html) [html](https://covid19tracker.ca/vaccinationtracker.html).
	- [\[](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5)27] Covid data tracker. [https://covid.cdc.gov/covid-data-tracker/](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5) [#vaccinations\\_vacc-people-booster-percent-pop5](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5).
- <sup>325</sup> [28] Cystat.gov. <https://www.cystat.gov.cy/el/default?OpenElement>.
	- [29] Ekonomik ve sosyal göstergeler. <https://www.devplan.org/seg-tr.html>.
	- [30] Eritrea. <https://www.who.int/countries/eri/>.
	- [31] Falklands.gov. <https://www.falklands.gov.fk/policy/statistics/census>.
	- [\[](https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1/)32] Données relatives aux personnes vaccinées contre la covid-19. [https://www.data.gouv.fr/](https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1/)
- <sup>330</sup> [fr/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1/](https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1/).
	- [33] Impfdashboard.de. <https://impfdashboard.de/daten>.
	- [\[](https://www.gov.gg/population)34] Electronic census; latest population, employment and earnings. [https://www.gov.gg/](https://www.gov.gg/population) [population](https://www.gov.gg/population).
- [\[](https://www.gov.je/Health/Coronavirus/Pages/CoronavirusCases.aspx#tab_vaccinationReporting)35] Coronavirus (covid-19) data for jersey. [https://www.gov.je/Health/Coronavirus/](https://www.gov.je/Health/Coronavirus/Pages/CoronavirusCases.aspx#tab_vaccinationReporting) <sup>335</sup> [Pages/CoronavirusCases.aspx#tab\\_vaccinationReporting](https://www.gov.je/Health/Coronavirus/Pages/CoronavirusCases.aspx#tab_vaccinationReporting).
	- [\[](https://www.gov.je/News/2019/Pages/Population-estimate-for-2018-released.aspx)36] Population estimate for 2018 released. [https://www.gov.je/News/2019/Pages/](https://www.gov.je/News/2019/Pages/Population-estimate-for-2018-released.aspx) [Population-estimate-for-2018-released.aspx](https://www.gov.je/News/2019/Pages/Population-estimate-for-2018-released.aspx).
	- [37] Citf-malaysia. <https://github.com/CITF-Malaysia/citf-public>.
	- [38] Covid19-malta. <https://github.com/COVID19-Malta/COVID19-Data>.

- <sup>340</sup> [\[](https://nso.gov.mt/en/News_Releases/Documents/2021/07/News2021_122.pdf)39] News release. [https://nso.gov.mt/en/News\\_Releases/Documents/2021/07/](https://nso.gov.mt/en/News_Releases/Documents/2021/07/News2021_122.pdf) [News2021\\_122.pdf](https://nso.gov.mt/en/News_Releases/Documents/2021/07/News2021_122.pdf).
- [40] Numărul populației cu resedinta obisnuită în republica moldova pe sexe și grupe vârstă la începutul anului 2019. [https://statistica.gov.md/ro/](https://statistica.gov.md/ro/numarul-populatiei-cu-resedinta-obisnuita-in-republica-moldova-pe-sexe-9578_3178.html) [numarul-populatiei-cu-resedinta-obisnuita-in-republica-moldova-pe-se](https://statistica.gov.md/ro/numarul-populatiei-cu-resedinta-obisnuita-in-republica-moldova-pe-sexe-9578_3178.html)xe-9578\_ <sup>345</sup> [3178.html](https://statistica.gov.md/ro/numarul-populatiei-cu-resedinta-obisnuita-in-republica-moldova-pe-sexe-9578_3178.html).

- [\[](https://ourworldindata.org/covid-vaccinations)41] Coronavirus (covid-19) vaccinations. [https://ourworldindata.org/](https://ourworldindata.org/covid-vaccinations) [covid-vaccinations](https://ourworldindata.org/covid-vaccinations).
- [\[](https://www.sabagov.com/post/successful-second-vaccination-round)42] The official website of the island government of public entity saba. [https://www.sabagov.](https://www.sabagov.com/post/successful-second-vaccination-round) [com/post/successful-second-vaccination-round](https://www.sabagov.com/post/successful-second-vaccination-round).
- <sup>350</sup> [\[](https://www.statiagovernment.com/key-topics/covid-19/vaccination-covid-19)43] Vaccination covid-19. [https://www.statiagovernment.com/key-topics/](https://www.statiagovernment.com/key-topics/covid-19/vaccination-covid-19) [covid-19/vaccination-covid-19](https://www.statiagovernment.com/key-topics/covid-19/vaccination-covid-19).
	- [44] Population. <https://www.sainthelena.gov.sh/population-150321/>.
	- [\[](https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/vacunaCovid19.htm)45] Vacuna covid-19. [https://www.sanidad.gob.es/profesionales/saludPublica/](https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/vacunaCovid19.htm) [ccayes/alertasActual/nCov/vacunaCovid19.htm](https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/vacunaCovid19.htm).
- <sup>355</sup> [\[](https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83698NED/table?ts=1578654405815)46] Caribisch nederland; bevolking; geslacht, leeftijd, burgerlijke staat. [https://opendata.cbs.](https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83698NED/table?ts=1578654405815) [nl/statline/#/CBS/nl/dataset/83698NED/table?ts=1578654405815](https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83698NED/table?ts=1578654405815).
	- [47] National statistics. <https://eng.stat.gov.tw/point.asp?index=9>.
	- [48] Tristan da cunha families. <https://www.tristandc.com/population.php>.
- [\[](https://coronavirus.data.gov.uk/details/vaccinations)49] Vaccinations in the united kingdom. [https://coronavirus.data.gov.uk/details/](https://coronavirus.data.gov.uk/details/vaccinations) <sup>360</sup> [vaccinations](https://coronavirus.data.gov.uk/details/vaccinations).
	- [50] Estimates of the population for the uk, england and wales, scotland and northern ireland. [https://www.ons.gov.uk/peoplepopulationandcommunity/](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland) [populationandmigration/populationestimates/datasets/](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland) [populationestimatesforukenglandandwalesscotlandandnorthernireland](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland).
- 365 [\[](https://population.un.org/wpp/Download/Standard/Population/)51] Population division world population prospects 2022. [https://population.un.org/wpp/](https://population.un.org/wpp/Download/Standard/Population/) [Download/Standard/Population/](https://population.un.org/wpp/Download/Standard/Population/).
	- [\[](https://data.census.gov/cedsci/table?q=population&t=Populations%20and%20People&g=0100000US,%240400000&y=2020&tid=DECENNIALPL2020.P1&hidePreview=true&tp=true)52] United states census bureau. [https://data.census.gov/cedsci/table?q=](https://data.census.gov/cedsci/table?q=population&t=Populations%20and%20People&g=0100000US,%240400000&y=2020&tid=DECENNIALPL2020.P1&hidePreview=true&tp=true) [population&t=Populations%20and%20People&g=0100000US,%240400000&y=](https://data.census.gov/cedsci/table?q=population&t=Populations%20and%20People&g=0100000US,%240400000&y=2020&tid=DECENNIALPL2020.P1&hidePreview=true&tp=true) [2020&tid=DECENNIALPL2020.P1&hidePreview=true&tp=true](https://data.census.gov/cedsci/table?q=population&t=Populations%20and%20People&g=0100000US,%240400000&y=2020&tid=DECENNIALPL2020.P1&hidePreview=true&tp=true).
- <span id="page-13-1"></span><span id="page-13-0"></span><sup>370</sup> [\[](https://www.vaticanstate.va/it/stato-governo/note-generali/popolazione.html)53] Popolazione. [https://www.vaticanstate.va/it/stato-governo/](https://www.vaticanstate.va/it/stato-governo/note-generali/popolazione.html) [note-generali/popolazione.html](https://www.vaticanstate.va/it/stato-governo/note-generali/popolazione.html).
	- [54] Who coronavirus (covid-19) dashboard. <https://covid19.who.int/info>.
	- [55] Population, total. <https://data.worldbank.org/indicator/SP.POP.TOTL>.
	- [56] The world bank. <https://data.worldbank.org/indicator/NY.GDP.MKTP.CD>.

- <span id="page-14-1"></span><span id="page-14-0"></span><sup>375</sup> [\[](https://www.pcbs.gov.ps/statisticsIndicatorsTables.aspx?lang=en&table_id=1084)57] Palestinian central bureau of statistics. [https://www.pcbs.gov.ps/](https://www.pcbs.gov.ps/statisticsIndicatorsTables.aspx?lang=en&table_id=1084) [statisticsIndicatorsTables.aspx?lang=en&table\\_id=1084](https://www.pcbs.gov.ps/statisticsIndicatorsTables.aspx?lang=en&table_id=1084).
	- [58] Crawford S Holling. The components of predation as revealed by a study of small-mammal predation of the european pine sawfly1. *The Canadian Entomologist*, 91(5):293–320, 1959.
- <span id="page-14-3"></span><span id="page-14-2"></span>[59] Leonor Michaelis, Maud L Menten, et al. Die kinetik der invertinwirkung. *Biochem. z*, 49(333- <sup>380</sup> 369):352, 1913.
	- [60] Ryan J Hum, Prabhat Jha, Anita M McGahan, and Yu-Ling Cheng. Global divergence in critical income for adult and childhood survival: analyses of mortality using michaelis–menten. *Elife*, 1:e00051, 2012.
- <span id="page-14-4"></span>[\[](https://mclust-org.github.io/mclust/reference/Mclust.html)61] Model-based clustering. [https://mclust-org.github.io/mclust/reference/](https://mclust-org.github.io/mclust/reference/Mclust.html) <sup>385</sup> [Mclust.html](https://mclust-org.github.io/mclust/reference/Mclust.html).
- <span id="page-14-5"></span>[62] Aaloke Mody, Cory Bradley, Salil Redkar, Branson Fox, Ingrid Eshun-Wilson, Matifadza G Hlatshwayo, Anne Trolard, Khai Hoan Tram, Lindsey M Filiatreau, Franda Thomas, et al. Quantifying inequities in covid-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in st. louis and kansas city, missouri. *PLoS medicine*, <sup>390</sup> 19(8):e1004048, 2022.
	- [63] Kelsey Lucyk, Kimberley A Simmonds, Diane L Lorenzetti, Steven J Drews, Lawrence W Svenson, and Margaret L Russell. The association between influenza vaccination and socioeconomic status in high income countries varies by the measure used: a systematic review. *BMC medical research methodology*, 19(1):1–23, 2019.
- <sup>395</sup> [64] Chadi M Saad-Roy, Sinead E Morris, C Jessica E Metcalf, Michael J Mina, Rachel E Baker, Jeremy Farrar, Edward C Holmes, Oliver G Pybus, Andrea L Graham, Simon A Levin, et al. Epidemiological and evolutionary considerations of sars-cov-2 vaccine dosing regimes. *Science*, 372(6540):363–370, 2021.
- <span id="page-14-8"></span>[65] Jeanette B Ruiz and Robert A Bell. Predictors of intention to vaccinate against covid-19: Results of a <sup>400</sup> nationwide survey. *Vaccine*, 39(7):1080–1086, 2021.
	- [66] Michael Siegel, Isabella Critchfield-Jain, Matthew Boykin, Alicia Owens, Rebeckah Muratore, Taiylor Nunn, and Joanne Oh. Racial/ethnic disparities in state-level covid-19 vaccination rates and their association with structural racism. *Journal of Racial and Ethnic Health Disparities*, pages 1–14, 2021.
- [67] Vaughn Barry, Sharoda Dasgupta, Daniel L Weller, Jennifer L Kriss, Betsy L Cadwell, Charles Rose, <sup>405</sup> Cassandra Pingali, Trieste Musial, J Danielle Sharpe, Stephen A Flores, et al. Patterns in covid-19 vaccination coverage, by social vulnerability and urbanicity—united states, december 14, 2020–may 1, 2021. *Morbidity and Mortality Weekly Report*, 70(22):818, 2021.
- <span id="page-14-10"></span><span id="page-14-9"></span>[68] Malorie Perry, Ashley Akbari, Simon Cottrell, Michael B Gravenor, Richard Roberts, Ronan A Lyons, Stuart Bedston, Fatemah Torabi, and Lucy Griffiths. Inequalities in coverage of covid-19 vaccination: <sup>410</sup> a population register based cross-sectional study in wales, uk. *Vaccine*, 39(42):6256–6261, 2021.
	- - [69] Rahul Subramanian, Qixin He, and Mercedes Pascual. Quantifying asymptomatic infection and transmission of covid-19 in new york city using observed cases, serology, and testing capacity. *Proceedings of the National Academy of Sciences*, 118(9):e2019716118, 2021.

<span id="page-14-7"></span><span id="page-14-6"></span>

<span id="page-15-0"></span>[\[](https://unstats.un.org/unsd/demographic-social/products/dyb/index.cshtml#overview)70] Demographic and social statistics. [https://unstats.un.org/unsd/](https://unstats.un.org/unsd/demographic-social/products/dyb/index.cshtml#overview) <sup>415</sup> [demographic-social/products/dyb/index.cshtml#overview](https://unstats.un.org/unsd/demographic-social/products/dyb/index.cshtml#overview).

- 
- <span id="page-15-1"></span>[\[](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html)71] Covid-19 pandemic planning scenarios. [https://www.cdc.gov/coronavirus/](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html) [2019-ncov/hcp/planning-scenarios.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html).
- <span id="page-15-2"></span>[72] Sara Y Tartof, Jeff M Slezak, Heidi Fischer, Vennis Hong, Bradley K Ackerson, Omesh N Ranasinghe, Timothy B Frankland, Oluwaseye A Ogun, Joann M Zamparo, Sharon Gray, et al. Effectiveness of <sup>420</sup> mrna bnt162b2 covid-19 vaccine up to 6 months in a large integrated health system in the usa: a retrospective cohort study. *The Lancet*, 398(10309):1407–1416, 2021.
	- [73] Alejandro Jara, Eduardo A Undurraga, Cecilia González, Fabio Paredes, Tomás Fontecilla, Gonzalo Jara, Alejandra Pizarro, Johanna Acevedo, Katherinne Leo, Francisco Leon, et al. Effectiveness of an inactivated sars-cov-2 vaccine in chile. *New England Journal of Medicine*, 385(10):875–884, 2021.
- <span id="page-15-4"></span><span id="page-15-3"></span><sup>425</sup> [74] Muge Cevik, Julia L Marcus, Caroline Buckee, and Tara C Smith. Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) transmission dynamics should inform policy. *Clinical Infectious Diseases*, 73(Supplement 2):S170–S176, 2021.
	- [75] Muge Cevik and Stefan D Baral. Networks of sars-cov-2 transmission. *Science*, 373(6551):162–163, 2021.
- <span id="page-15-6"></span><span id="page-15-5"></span>430 [76] Eszter Bokányi, Sándor Juhász, Márton Karsai, and Balázs Lengyel. Universal patterns of longdistance commuting and social assortativity in cities. *Scientific reports*, 11(1):1–10, 2021.
- [77] Margarita L Martinez-Fierro, Jorge Ríos-Jasso, Idalia Garza-Veloz, Lucia Reyes-Veyna, Rosa Maria Cerda-Luna, Iliana Duque-Jara, Maribel Galvan-Jimenez, Leticia A Ramirez-Hernandez, Andres Morales-Esquivel, Yolanda Ortiz-Castro, et al. The role of close contacts of covid-19 patients in the <sup>435</sup> sars-cov-2 transmission: an emphasis on the percentage of nonevaluated positivity in mexico. *American journal of infection control*, 49(1):15–20, 2021.
	- [\[](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html)78] Ending isolation and precautions for people with covid-19: Interim guidance. [https://www.cdc.](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html) [gov/coronavirus/2019-ncov/hcp/duration-isolation.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html).
- [79] Ashish Goyal, Daniel B Reeves, E Fabian Cardozo-Ojeda, Joshua T Schiffer, and Bryan T Mayer. <sup>440</sup> Viral load and contact heterogeneity predict sars-cov-2 transmission and super-spreading events. *Elife*, 10:e63537, 2021.
	- [80] Olha Puhach, Benjamin Meyer, and Isabella Eckerle. Sars-cov-2 viral load and shedding kinetics. *Nature Reviews Microbiology*, pages 1–15, 2022.
- [81] Ruiyun Li, Ottar N Bjørnstad, and Nils Chr Stenseth. Prioritizing vaccination by age and social activity <sup>445</sup> to advance societal health benefits in norway: a modelling study. *The Lancet Regional Health-Europe*, 10:100200, 2021.